<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: April 15, 1999
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing that Merrill Biel, M.D., Ph.D., has joined the Photogen Scientific
Advisory Council. The Press Release dated April 15, 1999 is attached as Exhibit
99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated April 15, 1999, announcing that
Merrill Biel, M.D., Ph.D., has joined the Photogen Scientific
Advisory Council.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
John Smolik, President
Date: April 27, 1999
<PAGE>
EXHIBIT INDEX
Exhibit Description
No.
99 Press release of the Company, dated April 15, 1999, announcing
that Merrill Biel, M.D., Ph.D., has joined the Photogen
Scientific Advisory Council.
<PAGE>
Exhibit 99
AT THE COMPANY:
JOHN SMOLIK
PRESIDENT & CEO
(423) 769-4012
COMPANY PRESS RELEASE
SOURCE: PHOTOGEN TECHNOLOGIES, INC.
Dr. Merrill Biel Joins Photogen Technologies'
Scientific Advisory Council
Leading Oncologist Offers Practical Experience, In-depth Knowledge Of
Conventional Photodynamic Therapy and Strong Research Background
KNOXVILLE, Tenn., April 15 /PRNewswire/ -- Photogen Technologies, Inc. (OTC
Bulletin Board: PHGN - news), today announced the appointment of Merrill A.
Biel, M.D., Ph.D., to its Scientific Advisory Council. The addition of Dr. Biel
increases the Council to three outside members. Photogen's Scientific Advisory
Council was formed in October 1998 with Daniel Tosteson, M.D., retired Dean of
Harvard Medical School, and Harry Morrison, Ph.D., Dean of Purdue School of
Science, as its members.
Dr. Biel is a practicing physician with more than 18 years experience in
surgery; head and neck oncology; and ear, nose and throat disorders. He is
currently president of Ear, Nose & Throat SpecialtyCare of Minnesota as well as
president and chief executive officer of Advanced Photodynamic Technologies,
Inc. Dr. Biel brings the user's perspective to Photogen's Advisory Council. His
practical skills are complemented by his intimate hands-on research experience
in Phase II and Phase III clinical studies involving work in several
disciplines, most predominantly, cancer and photodynamic therapy.
Commenting on the appointment, Photogen's Chief Executive Officer, John Smolik,
said, "Dr. Biel's practical, academic, research and management experience,
acquired over 18 years with some of the nation's leading medical centers, is
recognized internationally. His appointment to our Scientific Advisory Council
enhances the breadth of expertise available to us in bringing products from the
research laboratory through development to successful regulatory approval. His
engagement as a consultant will complement the scientific expertise of Drs.
Tosteson and Morrison."
Smolik added, "As we continue to expand our work in the testing, development
and manufacture of photodynamic therapeutics, Dr. Biel's magnitude of experience
will be extremely helpful. We are intensifying our pre-clinical studies this
year, and already have
<PAGE>
trials underway utilizing our proprietary multi-photon activating technology in
combination with photoactive compounds to treat two complex eye disorders --
ocular melanoma and advanced maculardegeneration. Currently no effective
existing therapy is available for either of these indications. Additionally, we
will soon begin studying the use of a well-known compound as a photoactive drug
with potential to effectively interact with x-ray energy to destroy cancer cells
- -- adding an important new dimension to our capabilities in photodynamic
therapy."
Photogen Technologies, Inc. is a development-stage company focused on creating
photodynamic-related health-care products based on its proprietary multi-photon
excitation and other related technologies. The company has discovered new
methods for using laser-generated light to activate photoactive agents within
deep tissue sufficient to produce a range of beneficial therapeutic and
diagnostic outcomes. These technologies involve methods, materials and devices
that may be used to produce light and photoactive agents that will destroy
diseased cells, remove tissue or identify and diagnose disease. The company has
no products or operating revenues at this time.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks and uncertainties include: the ability of the company to
develop a product and obtain regulatory approval for its use; the ability of
the company to successfully market and sell any products and equipment; the
company's ability to manufacture products in sufficient quantities; the
company's ability to maintain intellectual property protection for its
proprietary products, to defend its existing intellectual property rights
from challenges by third parties, and to avoid infringing intellectual
property rights of third parties; unforeseen operating risks; the company's
ability to secure collaborative agreements with third parties for various
research, development, manufacturing, marketing and other functions;
competition; risks associated with the dependence on manufacturers of the
company's proposed products; the availability of capital to finance planned
activities; and the extent to which the clinicians performing the procedures
are able to obtain third-party reimbursement. These risks are qualified in
their entirety by cautionary language and risk factors set forth in the
company's filings with the Securities and Exchange Commission.
SOURCE: Photogen Technologies, Inc.
